US Pharma MarketingFDA extends Beren’s rare disease review after info request, further stretching saga
FDA extends Beren’s rare disease review after info request, further stretching saga is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path toward the U.S. market.
Source: FierceBiotech